Stryker (SYK) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Stryker reported revenue of $5.87 billion for the quarter ended March 2025, reflecting an 11.9% increase year-over-year and surpassing the Zacks Consensus Estimate of$ 5.7 billion by 2.88% [1] - The company's EPS for the quarter was $2.84, up from$ 2.50 in the same quarter last year, exceeding the consensus estimate of $2.73 by 4.03% [1] Financial Performance - Net sales in the United States reached$ 4.44 billion, exceeding the average analyst estimate of $4.25 billion, representing a year-over-year increase of 13.4% [4] - International net sales totaled$ 1.43 billion, slightly below the average estimate of $1.44 billion, with a year-over-year growth of 7.3% [4] - Orthopaedics net sales amounted to$ 2.36 billion, surpassing the average estimate of $2.31 billion, marking a 5% increase year-over-year [4] Segment Performance - MedSurg and Neurotechnology sales were reported at$ 3.51 billion, exceeding the average estimate of $3.41 billion, with a significant year-over-year increase of 17.1% [4] - Orthopaedics- Trauma and Extremities sales reached$ 945 million, above the average estimate of $902.89 million, reflecting a 13.9% year-over-year increase [4] - Orthopaedics- Spinal Implants sales were$ 166 million, falling short of the average estimate of $172.83 million, showing a substantial year-over-year decline of 44.7% [4] Stock Performance - Stryker's shares have returned +1.6% over the past month, contrasting with a -0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]